To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

Phase 3CompletedNCT00141388

Pfizer455 enrolled

Overview

To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

455

Conditions

Seizure Disorder, Partial

Interventions

PregabalinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have met the inclusion criteria for the preceding double-blind study * Have received double-blind study medication and wish to receive open-label pregabalin. Exclusion Criteria: * Cannot have absence seizures.

Locations (56)

Outcomes

Primary Outcomes

Safety Efficacy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Birmingham, Alabama, United States

Pfizer Investigational Site

Birmingham, Alabama, United States

Pfizer Investigational Site

Birmingham, Alabama, United States

Pfizer Investigational Site

Phoenix, Arizona, United States

Pfizer Investigational Site

Tucson, Arizona, United States

Pfizer Investigational Site

Tucson, Arizona, United States

Pfizer Investigational Site

Little Rock, Arkansas, United States

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Pasadena, California, United States

Pfizer Investigational Site

Gainesville, Florida, United States

...and 46 more locations